StockData

Camp4 Therapeutics vs NewAmsterdam Pharma

CAMP and NAMS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CAMP and NAMS compare

Camp4 Therapeutics grew revenue faster over the last twelve months (40.2% versus −88.9% for NewAmsterdam Pharma).

Camp4 Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2544% compared with −3644% at NewAmsterdam Pharma.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCAMPNAMS
Size and price
Market cap$251M–
Share price$4.00$19.39
Change, 1 year−2.4%−49.4%
Change, 5 years−98.2%98.1%
Beta (5Y)1.481.57
Employees48100
StockData Score
Total score66
Valuation score00
Growth score1 (better)0
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S59.5×–
FCF yield−11.4%–
Growth
Revenue growth (TTM)40.2% (better)−88.9%
Profitability
Operating margin−1254% (better)−3432%
Net margin−2544% (better)−3644%
FCF margin−681% (better)−2018%
Return on equity−546%−36.8% (better)
Return on invested capital–−1046%
Financial health
Debt / equity–0.00
Current ratio4.709.03 (better)
Altman Z-score−4.47–
Piotroski F-score4 (better)3
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%–
Ownership
Held by institutions66.5%–
Held by insiders21.7%22.0%
Insider net buying, 12 months−$2.4M (better)−$63.0M
Short interest, % of float6.6%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.